A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Apr 2019
At a glance
- Drugs Regorafenib (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms RESORCE
- Sponsors Bayer; Bayer HealthCare
- 09 Apr 2019 Planned End Date changed from 31 Dec 2019 to 27 Sep 2019.
- 24 Feb 2019 Planned End Date changed from 31 May 2019 to 31 Dec 2019.
- 06 Feb 2019 A preplanned, retrospective biomarker analysis results (n=573) were published in the Gastroenterology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History